Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Referenzen zu: DGU, EAU, AUA, ASCO 2007: Relevantes und Innovatives für die Urologische Onkologie in Klinik und Praxis UPDATE PRPOSTATAKARZINOM P. J. Olbert Klinik für Urologie und Kinderurologie, Philipps-Universität Marburg, Baldingerstrasse, D-35043 Marburg 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. Ulmert D et al. Value of PSA measured in middle age in predicting diagnosis of advanced prostate cancer in an unscreened population. J Clin Oncol 25, 18S (2007): 236S Abstract 5006 Rettig BM et al. Evaluation of pomegranate polyphenol – mediated suppression of nuclear factor kappa B activity in prostate cancer cell lines. J Urol 177, 4 Suppl. (2007): 46 Abstract 137 Srivastava JK et al. Tocorienol-rich fraction of palm oil leads to growth inhibition and apoptosis of PC-3 tumor xenografts in athymic nude mice. J Urol 177, 4 Suppl. (2007): 46 Abstract 138 Venkatesvaran V et al. Early commencement of micronutrients is beneficial in reducing the incidence of prostate cancer. J Urol 177, 4 Suppl. (2007): 47 Abstract 139 van Oort IM et al. The 2002 TNM subclassification of unilateral pT2 prostate cancer is not relevant. J Urol 177, 4 Suppl. (2007): 112 Abstract 331 Cohen MS et al. A meta-analysis evaluating the accuracy of prostate Gleason biopsy in over 11.000 patients. J Urol 177, 4 Suppl. (2007): 249 Abstract 743 Jeldres C et al. The role of digital rectal examitation in prediction of pathological stage after radical prostatectomy in contemporary patients. J Urol 177, 4 Suppl. (2007): 337 Abstract 1023 Bolla M et al. Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation for locally advanced prostate cancer: 6 months versus 3 years ADT – results of the randomized EORTC phase III trial 22961. J Clin Oncol 25, 18S (2007): 238S Abstract 5014 Souhami L et al. The impact of the duration of adjuvant hormonal therapy in patients with unfavourable prognosis prostate cancer treated with radiotherapy: secondary results of RTOG 85-31. J Clin Oncol 25, 18S (2007): 250S Abstract 5062 Association of cerebrovascular accident and myocardial infarction with androgen deprivation therapy. Malcolm JB et al. J Urol 177, 4 Suppl. (2007): 200 Abstract 597 Increased risk of newly diagnosed comorbidities in porstate cancer patients treated with androgen deprivation therapy. J Urol 177, 4 Suppl. (2007): 200 Abstract 598 Tsai HK et al. Androgen deprivation therapy for prostate cancer and the risk of cardiac mortality. J Urol 177, 4 Suppl. (2007): 124 Abstract 378 Touijer K et al. Comprehensive, prospective, comparative analysis of outcomes between open and laparoscopic radical prostatectomy. J Urol 177, 4 Suppl. (2007): 184 Abstract 553 14. 15. 16. 17. 18. 19. 20. 21. Tunn U et al. Intermittent androgen deprivation in patients with PSA-relapse after radical prostatectomy. Final results of a European, randomized prospective phase III clinical trial. J Urol 177, 4 Suppl. (2007): 201 Abstract 600 Briganti A et al. Excellent long term outcome of patients with low volume of lymph node invasion treated with extended pelvic lymph node dissection at the time of radical prostatectomy. J Urol 177, 4 Suppl. (2007): 243 Abstract 724 Freedland SJ et al. Radical prostatectomy for clinical stage T3 disease. J Urol 177, 4 Suppl. (2007): 243 Abstract 725 Berthold DR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival of the TAX 327 study. J Clin Oncol 25, 18S (2007): 236S Abstract 5005 Armstrong AJ et al. Analysis of prostate specific antigen decline as a surrogate for overall survival in metastatic hormone refractory prostate cancer (HRPCA). J Clin Oncol 25, 18S (2007): 237S Abstract 5009 Miller K et al. Randomized prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer. J Clin Oncol 25, 18S (2007): 238S Abstract 5015 Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: Results of a randomised phase III trial. J Clin Oncol 25, 18S (2007): 239S Abstract 5019 Machiels JH et al. Phase III trial of docetaxel (D), estramustine (E) and prednisone versus docetaxel plus prednisone in patients with metastatic hormone refractory prostate cancer (HRPC). J Clin Oncol 25, 18S (2007): 250S Abstract 5067